Halozyme Therapeutics (HALO) News Today $64.26 +0.24 (+0.38%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Advantage Alpha Capital Partners LPAdvantage Alpha Capital Partners LP lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 38.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,033 shares of the biopharmaceutical company's stock aMarch 25 at 5:05 AM | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month High - Here's WhyHalozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year High - What's Next?March 25 at 4:30 AM | marketbeat.comMarietta Investment Partners LLC Sells 52,728 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Marietta Investment Partners LLC lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 76.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 16,401 shares of the biopharmaceutical company's stock after selling 52,728 sharMarch 23 at 7:02 AM | marketbeat.comHalozyme announces CTO retirement, effective immediatelyMarch 23 at 6:00 AM | investing.comCibc World Markets Corp Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Cibc World Markets Corp purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 11,674 shares of the biopharmaceutical company's stock, valuedMarch 23 at 3:52 AM | marketbeat.comBoston Partners Lowers Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Boston Partners cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 407,984 shares of the biopharmaceutical company'sMarch 22 at 4:45 AM | marketbeat.comLENZ Therapeutics (LENZ) Gets a Buy from Piper SandlerMarch 21, 2025 | markets.businessinsider.comLindenwold Advisors INC Buys New Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Lindenwold Advisors INC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 5,000 shares of the biopharmaceutical company'sMarch 20, 2025 | marketbeat.comIntech Investment Management LLC Purchases 83,105 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Intech Investment Management LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 147.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 139,410 shares of the biophMarch 20, 2025 | marketbeat.comSouth Street Advisors LLC Boosts Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)South Street Advisors LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 34.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 229,765 shares of the biopharmaceuticalMarch 19, 2025 | marketbeat.comRoyce & Associates LP Has $9.42 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Royce & Associates LP lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 58.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 196,999 shares of the biopharmaceutical company's stoMarch 19, 2025 | marketbeat.com40,948 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 40,948 shares of the biopharmaceutical company's stock, valuedMarch 19, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Sells 15,527 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Skandinaviska Enskilda Banken AB publ trimmed its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 32.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,100 shares of the biopharmaceuticalMarch 18, 2025 | marketbeat.comGreat Lakes Advisors LLC Sells 18,237 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Great Lakes Advisors LLC decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 22.1% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 64,098 shares of the biopharmaceutical company's stock after selling 18,237March 16, 2025 | marketbeat.comWealthfront Advisers LLC Acquires Shares of 43,835 Halozyme Therapeutics, Inc. (NASDAQ:HALO)Wealthfront Advisers LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 43,835 shares of the biopharmaceutical company's stock, valued at approximately $2,096,March 16, 2025 | marketbeat.comRaymond James Financial Inc. Buys Shares of 456,774 Halozyme Therapeutics, Inc. (NASDAQ:HALO)Raymond James Financial Inc. bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 456,774 shares of the biopharmaceutical company's stock, valued at apprMarch 16, 2025 | marketbeat.comZacks Research Issues Positive Estimate for HALO EarningsMarch 16, 2025 | americanbankingnews.comQ2 EPS Estimate for Halozyme Therapeutics Boosted by AnalystHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities research analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now expectsMarch 15, 2025 | marketbeat.comZacks Research Has Pessimistic Outlook of HALO Q1 EarningsMarch 15, 2025 | americanbankingnews.comHalozyme Therapeutics: Steady Growth In A Challenged MarketMarch 14, 2025 | seekingalpha.comZacks Research Issues Pessimistic Estimate for HALO EarningsHalozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities researchers at Zacks Research cut their Q1 2025 earnings estimates for shares of Halozyme Therapeutics in a research report issued on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the biopharmaceuticalMarch 14, 2025 | marketbeat.comHalozyme Stock Offers Early Buy Point As Company Hits $1 Billion In RevenueMarch 14, 2025 | msn.comEdgestream Partners L.P. Sells 69,781 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Edgestream Partners L.P. trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 81.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,220 shares of the biopharmaceutical company's stocMarch 12, 2025 | marketbeat.comIsthmus Partners LLC Purchases Shares of 6,706 Halozyme Therapeutics, Inc. (NASDAQ:HALO)Isthmus Partners LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 6,706 shares of the biopharmaceutical company's stock, valued at appMarch 11, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Buys 9,780 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Charles Schwab Investment Management Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,783,177 shares of the biopharmaceuMarch 11, 2025 | marketbeat.comArtisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s WhyMarch 10, 2025 | msn.comFuture Fund LLC Buys 6,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Future Fund LLC grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 58.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 17,596 shares of the biopharmaceutical company's stock after acquirinMarch 10, 2025 | marketbeat.comVictory Capital Management Inc. Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Victory Capital Management Inc. grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 60.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 650,751 shares of the biopharmaceMarch 10, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Mesirow Financial Investment Management Inc.Mesirow Financial Investment Management Inc. lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 129.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,494 shares of the biopMarch 9, 2025 | marketbeat.comAssetmark Inc. Acquires 9,612 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Assetmark Inc. lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 102,771 shares of the biopharmaceutical compMarch 9, 2025 | marketbeat.comJackson Creek Investment Advisors LLC Invests $1.26 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Jackson Creek Investment Advisors LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 26,426 shares of the biopharmMarch 8, 2025 | marketbeat.comHalozyme Therapeutics' (HALO) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday.March 7, 2025 | marketbeat.comPiper Sandler Keeps Their Hold Rating on Halozyme (HALO)March 6, 2025 | markets.businessinsider.comNew version of Merck's Keytruda faces possible patent battle, WSJ reportsMarch 5, 2025 | msn.comMerck set for patent battle with Halozyme over injectable Keytruda: WSJMarch 5, 2025 | msn.com62,000 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Bought by Clark Estates Inc. NYClark Estates Inc. NY acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 62,000 shares of the biopharmaceutMarch 5, 2025 | marketbeat.comJeffrey William Henderson Sells 5,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the transaction, the director now owns 33,611 shares in the company, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.March 4, 2025 | marketbeat.comFisher Asset Management LLC Raises Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Fisher Asset Management LLC raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 414,719 shares of the biMarch 4, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Moderate Buy" by BrokeragesShares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and sMarch 4, 2025 | marketbeat.comInsider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme Therapeutics Inc (HALO)March 4, 2025 | gurufocus.com18,725 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Unified Investment ManagementUnified Investment Management purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 18,725 shares ofMarch 3, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Chase Investment Counsel CorpChase Investment Counsel Corp trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 71.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,691 shares of the biopharmaceutical company's stMarch 2, 2025 | marketbeat.comGW&K Investment Management LLC Sells 16,620 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)GW&K Investment Management LLC lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,745,641 shares of the biopharmaMarch 1, 2025 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $98,901.16 in StockHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.February 28, 2025 | marketbeat.comMichael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.February 28, 2025 | marketbeat.comInsider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells 1,697 Shares of StockFebruary 28, 2025 | insidertrades.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Los Angeles Capital Management LLCLos Angeles Capital Management LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 92,475 shares of the biopharmaceuticaFebruary 28, 2025 | marketbeat.comInsider Sell Alert: Michael Labarre Sells Shares of Halozyme Therapeutics Inc (HALO)February 27, 2025 | gurufocus.comHalozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings GuidanceHalozyme Therapeutics (NASDAQ:HALO) updated its FY 2025 earnings guidance. The company provided EPS guidance of 4.950-5.350 for the period, compared to the consensus estimate of 5.050. The company also issued revenue guidance of $1.2 billionillion-$1.2 billionillion, compared to the consensus estimate of $1.2 billionillion.February 27, 2025 | marketbeat.comPrivate Advisor Group LLC Acquires 5,745 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Private Advisor Group LLC boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 23.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,908 shares of the biopharmaceutiFebruary 27, 2025 | marketbeat.com Remove Ads Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Media Mentions By Week HALO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼1.350.63▲Average Medical News Sentiment HALO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼129▲HALO Articles Average Week Remove Ads Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today BMRN News Today INCY News Today NBIX News Today EXEL News Today EXAS News Today RGEN News Today MDGL News Today ALKS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
